Advanced Biomed Inc. (ADVB)
Nasdaq: ADVB · Services-Medical Laboratories · Reno, NV · filing with the SEC since 2022
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in June.| Fiscal year | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Period ending | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
| Report filed | Oct 13, 2026 | Oct 8, 2025 | · |
| Revenue | 127,637 | · | · |
| Research and development | · | 909,771 | 880,193 |
| General and administrative | 4,627,170 | 1,086,470r | 1,661,379 |
| Total operating expenses | 6,361,179 | 1,086,470r | 2,541,572 |
| Operating income | -6,233,542 | -1,086,470 | · |
| Interest and investment income | · | 24,915 | 53,495 |
| Interest income (expense), net | -7,014 | · | · |
| Other income (expense), net | -21,925 | -262,848 | -294,201 |
| Total non-operating income (expense) | -28,939 | -237,933 | -240,706 |
| Income before income taxes | -6,262,481 | -1,086,470r | -2,782,278 |
| Income tax expense | -1,205 | · | · |
| Income from continuing operations | -6,261,276 | -1,086,470 | · |
| Income from discontinued operations | 12,938,353 | -2,172,499 | · |
| Net income | 6,677,077 | -3,258,969 | -2,782,278 |
| Earnings per share, basic | 5.33 | -3.18r | -2.80b |
| Earnings per share, diluted | 5.33 | -3.18r | -2.80b |
| Weighted average shares, basic | 1,252,727 | 1,026,285r | 1,000,000b |
| Weighted average shares, diluted | 1,252,727 | 1,026,285r | 1,000,000b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-20 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitIncome from continuing operations profit from the businesses it keeps
us-gaap:IncomeLossFromContinuingOperationsIncome from discontinued operations profit or loss from businesses it sold or closed
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding